409 related articles for article (PubMed ID: 21684858)
1. [Recent advances in mutant p53 and novel personalized strategies for cancer therapy].
Lu SQ; Jia ST; Luo Y
Yi Chuan; 2011 Jun; 33(6):539-48. PubMed ID: 21684858
[TBL] [Abstract][Full Text] [Related]
2. Targeting mutant p53 for efficient cancer therapy.
Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
[TBL] [Abstract][Full Text] [Related]
4. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
5. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
Garufi A; Pistritto G; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
[TBL] [Abstract][Full Text] [Related]
6. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
7. [Advances on mutant p53 research].
Li DH; Zhang LQ; He FC
Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
[TBL] [Abstract][Full Text] [Related]
8. Induction of genetic instability by gain-of-function p53 cancer mutants.
Xu Y
Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological activation of p53 in cancer cells.
Athar M; Elmets CA; Kopelovich L
Curr Pharm Des; 2011; 17(6):631-9. PubMed ID: 21391904
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor p53 and its gain-of-function mutants in cancer.
Liu J; Zhang C; Feng Z
Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):170-9. PubMed ID: 24374774
[TBL] [Abstract][Full Text] [Related]
11. Novel cancer therapy by reactivation of the p53 apoptosis pathway.
Bykov VJ; Wiman KG
Ann Med; 2003; 35(7):458-65. PubMed ID: 14649328
[TBL] [Abstract][Full Text] [Related]
12. Disarming mutant p53 oncogenic function.
Girardini JE; Marotta C; Del Sal G
Pharmacol Res; 2014 Jan; 79():75-87. PubMed ID: 24246451
[TBL] [Abstract][Full Text] [Related]
13. Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer.
Blanden AR; Yu X; Loh SN; Levine AJ; Carpizo DR
Drug Discov Today; 2015 Nov; 20(11):1391-7. PubMed ID: 26205328
[TBL] [Abstract][Full Text] [Related]
14. Wild type p53 reactivation: from lab bench to clinic.
Selivanova G
FEBS Lett; 2014 Aug; 588(16):2628-38. PubMed ID: 24726725
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological reactivation of p53 as a strategy to treat cancer.
Zawacka-Pankau J; Selivanova G
J Intern Med; 2015 Feb; 277(2):248-259. PubMed ID: 25495071
[TBL] [Abstract][Full Text] [Related]
16. Awakening the "guardian of genome": reactivation of mutant p53.
Binayke A; Mishra S; Suman P; Das S; Chander H
Cancer Chemother Pharmacol; 2019 Jan; 83(1):1-15. PubMed ID: 30324219
[TBL] [Abstract][Full Text] [Related]
17. Chaperoning of mutant p53 protein by wild-type p53 protein causes hypoxic tumor regression.
Gogna R; Madan E; Kuppusamy P; Pati U
J Biol Chem; 2012 Jan; 287(4):2907-14. PubMed ID: 22147694
[TBL] [Abstract][Full Text] [Related]
18. Drug discovery and mutant p53.
Maslon MM; Hupp TR
Trends Cell Biol; 2010 Sep; 20(9):542-55. PubMed ID: 20656489
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 reactivation by small molecules makes its way to the clinic.
Bykov VJ; Wiman KG
FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
[TBL] [Abstract][Full Text] [Related]
20. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Blandino G; Di Agostino S
J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
